Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
-
J Obstet Gynaecol Can · Jul 2016
Temporal and Regional Variations in Operative Vaginal Delivery in Canada by Pelvic Station, 2004-2012.
To describe temporal and regional variations in Canada in the use of operative vaginal delivery (OVD) at term for singleton pregnancies by pelvic station between 2004 and 2013. ⋯ Temporal trends in OVD rates varied by pelvic station, with rates of outlet and low OVD increasing and rates of midpelvic and failed OVD decreasing. Vacuum extraction is increasingly replacing forceps deliveries at outlet and low stations, whereas Caesarean sections are replacing forceps deliveries at midpelvic stations. Variations in OVD rates across provinces suggest differences in instrument preference and/or an evolution in standards of practice.
-
J Obstet Gynaecol Can · Jun 2016
Consensus canadien sur la nutrition féminine : adolescence, reproduction, ménopause et au-delà.
Doter les professionnels de la santé du Canada de connaissances et d'outils de base, afin qu'ils puissent prodiguer des conseils nutritionnels aux femmes tout au long de leur cycle de vie. RéSULTATS: L'alimentation optimale a fait l'objet d'une évaluation tout au long du cycle de vie de la femme. Elle a porté en particulier sur l'adolescence, la préconception, la grossesse, la période post-partum, la ménopause et au-delà. Le présent guide fournit d'abord des directives abrégées à l'intention de toutes les femmes. Elles sont suivies de chapitres proposant un examen des données probantes, ainsi que des recommandations sur la promotion d'une alimentation saine et d'un poids santé à chaque étape de la vie. Par ailleurs, tous les chapitres présentent une analyse de nutriments d'intérêt particulier, ainsi que d'autres aspects uniques à chaque étape de la vie. DONNéES PROBANTES: Des documents publiés, des rapports d'organismes gouvernementaux et de santé, des lignes directrices de pratique clinique, de la documentation parallèle et des extraits de manuels ont servi à étayer les recommandations formulées dans le présent document. ⋯ L'évaluation de la qualité des données probantes repose sur les critères décrits dans le rapport du Groupe d'étude canadien sur les soins de santé préventifs. CHAPITRE 2 : CONSEILS GéNéRAUX SUR L'ALIMENTATION FéMININE: Déclarations Sommaires Recommandations CHAPITRE 3 : ALIMENTATION DE L'ADOLESCENTE: Déclarations Sommaires Recommandations CHAPITRE 4 : ALIMENTATION PRéCONCEPTIONNELLE: Déclarations Sommaires Recommandations CHAPITRE 5 : ALIMENTATION PENDANT LA GROSSESSE: Déclarations Sommaires Recommandations CHAPITRE 6 : ALIMENTATION ET LACTATION POST-PARTUM: Déclarations Sommaires Recommandations CHAPITRE 7 : ALIMENTATION PENDANT LA MéNOPAUSE ET AU-DELà: Déclarations Sommaires Recommandations.
-
J Obstet Gynaecol Can · Mar 2016
Case ReportsCervical Ectopic Pregnancy Complicated by Escherichia Coli Septicemia: A Case Report.
Cervical ectopic pregnancy is an uncommon form of ectopic pregnancy. The spectrum of treatment options includes systemic medical therapy, local injection with methotrexate and/or potassium chloride, surgery, or a combination of these modalities. ⋯ A cervical ectopic pregnancy can be complicated by E. coli septicemia.
-
J Obstet Gynaecol Can · Feb 2016
Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
To provide guidelines for health care providers on the use of contraceptive methods to prevent pregnancy and on the promotion of healthy sexuality. ⋯ 1. Intrauterine contraceptives are as effective as permanent contraception methods. (II-2) 2. The use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg by patients taking tamoxifen is not associated with recurrence of breast cancer. (I) 3. Intrauterine contraceptives have a number of noncontraceptive benefits. The levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg significantly decreases menstrual blood loss (I) and dysmenorrhea. (II-2) Both the copper intrauterine device and the LNG-IUS significantly decrease the risk of endometrial cancer. (II-2) 4. The risk of uterine perforation decreases with inserter experience but is higher in postpartum and breastfeeding women. (II-2) 5. The risk of pelvic inflammatory disease (PID) is increased slightly in the first month after intrauterine contraceptive (IUC) insertion, but the absolute risk is low. Exposure to sexually transmitted infections and not the IUC itself is responsible for PID occurring after the first month of use. (II-2) 6. Nulliparity is not associated with an increased risk of intrauterine contraceptive expulsion. (II-2) 7. Ectopic pregnancy with an intrauterine contraceptive (IUC) is rare, but when a pregnancy occurs with an IUC in situ, it is an ectopic pregnancy in 15% to 50% of the cases. (II-2) 8. In women who conceive with an intrauterine contraceptive (IUC) in place, early IUC removal improves outcomes but does not entirely eliminate risks. (II-2) 9. Intrauterine contraceptives do not increase the risk of infertility. (II-2) 10. Immediate insertion of an intrauterine contraceptive (10 minutes postplacental to 48 hours) postpartum or post-Caesarean section is associated with a higher continuation rate compared with insertion at 6 weeks postpartum. (I) 11. Immediate insertion of an intrauterine contraceptive (IUC; 10 minutes postplacental to 48 hours) postpartum or post-Caesarean section is associated with a higher risk of expulsion. (I) The benefit of inserting an IUC immediately postpartum or post-Caesarean section outweighs the disadvantages of increased risk of perforation and expulsion. (II-C) 12. Insertion of an intrauterine contraceptive in breastfeeding women is associated with a higher risk of uterine perforation in the first postpartum year. (II-2) 13. Immediate insertion of an intrauterine contraceptive (IUC) post-abortion significantly reduces the risk of repeat abortion (II-2) and increases IUC continuation rates at 6 months. (I) 14. Antibiotic prophylaxis for intrauterine contraceptive insertion does not significantly reduce postinsertion pelvic infection. (I) RECOMMENDATIONS: 1. Health care professionals should be careful not to restrict access to intrauterine contraceptives (IUC) owing to theoretical or unproven risks. (III-A) Health care professionals should offer IUCs as a first-line method of contraception to both nulliparous and multiparous women. (II-2A) 2. In women seeking intrauterine contraception (IUC) and presenting with heavy menstrual bleeding and/or dysmenorrhea, health care professionals should consider the use of the levonorgestrel intrauterine system 52 mg over other IUCs. (I-A) 3. Patients with breast cancer taking tamoxifen may consider a levonorgestrel-releasing intrauterine system 52 mg after consultation with their oncologist. (I-A) 4. Women requesting a levonorgestrel-releasing intrauterine system or a copper-intrauterine device should be counseled regarding changes in bleeding patterns, sexually transmitted infection risk, and duration of use. (III-A) 5. A health care professional should be reasonably certain that the woman is not pregnant prior to inserting an intrauterine contraceptive at any time during the menstrual cycle. (III-A) 6. Health care providers should consider inserting an intrauterine contraceptive immediately after an induced abortion rather than waiting for an interval insertion. (I-B) 7. In women who conceive with an intrauterine contraceptive (IUC) in place, the diagnosis of ectopic pregnancy should be excluded as arly as possible. (II-2A) Once an ectopic pregnancy has been excluded, the IUC should be removed without an invasive procedure. The IUC may be removed at the time of a surgical termination. (II-2B) 8. In the case of pelvic inflammatory disease, it is not necessary to remove the intrauterine contraceptive unless there is no clinical improvement after 48 to 72 hours of appropriate antibiotic treatment. (II-2B) 9. Routine antibiotic prophylaxis for intrauterine contraceptive (IUC) insertion is not indicated. (I-B) Health care providers should perform sexually transmitted infection (STI) testing in women at high risk of STI at the time of IUC insertion. If the test is positive for chlamydia and/or gonorrhea, the woman should be appropriately treated postinsertion and the IUC can remain in situ. (II-2B) 10. Unscheduled bleeding in intrauterine contraception users, when persistent or associated with pelvic pain, should be investigated to rule out infection, pregnancy, gynecological pathology, expulsion or malposition. (III-A)
-
J Obstet Gynaecol Can · Jan 2016
Maternal Risk Factors and Outcomes of Umbilical Cord Prolapse: A Population-Based Study.
Umbilical cord prolapse (UCP) is a rare event believed to be associated with adverse outcomes. The purpose of our study was to use a large administrative database to better identify incidence, predictors, and outcomes of births with UCP. ⋯ Although there are established risk factors, UCP occurs most commonly in low risk women at term. When possible, vaginal delivery is preferred in women with UCP because it appears to be associated with a lower risk of fetal injury.